Study Shows AccurKardia's AI-Enabled ECG Can Detect Aortic Stenosis Years Before Valve Replacement

The technology may improve mortality risk prediction and enable earlier intervention.

Published on Feb. 10, 2026

Got story updates? Submit your updates here. ›

AccurKardia, a company focused on ECG-based diagnostics, announced results from a study demonstrating that its AI-enabled ECG technology, AK-AVS, can detect aortic stenosis years before patients require valve replacement. The study found that AK-AVS can detect aortic stenosis up to 4.5 years before transcatheter aortic valve replacement (TAVR) intervention, potentially enabling earlier detection, monitoring, and better timing of treatment. The findings also showed that the AI-ECG model can independently predict increased one-year mortality risk following TAVR, identifying patient risk not captured by widely used clinical risk scores.

Why it matters

Aortic stenosis is a serious valvular heart disease that can lead to heart failure, hospitalization, and death if not diagnosed and treated early. This technology has the potential to transform how clinicians screen, monitor, and risk-stratify patients with aortic stenosis, allowing for earlier intervention and improved outcomes.

The details

The study, led by Dr. Matthew Segar of the Texas Heart Institute, evaluated AccurKardia's AK-AVS AI model across both community-based populations and patients who underwent TAVR. The study found that patients who screened positive for aortic stenosis using the AI-ECG but did not yet show disease on echocardiography still had a 4.4-fold increased risk of future aortic stenosis hospitalization, suggesting the model may identify early electrical changes in the heart before structural abnormalities are visible.

  • The study evaluated AccurKardia's AK-AVS AI model across both community-based populations and patients who underwent transcatheter aortic valve replacement (TAVR) at Baylor St. Luke's Medical Center.
  • The study found that AK-AVS can detect aortic stenosis through routine ECGs up to 4.5 years before TAVR intervention.

The players

AccurKardia

An ECG-led diagnostics software company focused on transforming ECG data into a more powerful diagnostic tool and broad biomarker to improve patient outcomes and save lives globally.

Dr. Matthew Segar

Cardiologist and principal investigator of the study, from the Texas Heart Institute.

Dr. David Shavelle

Chief of Cardiology for the MemorialCare Health System.

Got photos? Submit your photos here. ›

What they’re saying

“This study demonstrates that AK-AVS could not only enable earlier detection of aortic stenosis, but it may also be a useful tool in surveillance and predicting outcomes.”

— Dr. David Shavelle, Chief of Cardiology for the MemorialCare Health System (BusinessWire)

“By detecting subtle electrical remodeling patterns and tracking how they evolve over time, this technology has the potential to transform how clinicians screen, monitor, and risk-stratify patients, ultimately helping physicians intervene earlier and improve outcomes in aortic stenosis.”

— Dr. Matthew Segar, Cardiologist and principal investigator of the study (BusinessWire)

What’s next

AccurKardia's next step is to complete real-world pilots of AK-AVS to demonstrate its ability to identify undiagnosed aortic stenosis patients and inform their subsequent treatment.

The takeaway

This study highlights the potential of AI-enhanced ECG analysis to enable earlier detection, monitoring, and risk assessment of aortic stenosis, a serious heart condition that can lead to severe complications if not diagnosed and treated early. By expanding access to screening and risk assessment, this technology could help clinicians intervene sooner and improve outcomes for patients.